The global CAR-T drugs market, valued at USD 5.5 billion in 2025, is expected to grow to USD 18.03 billion by 2035, expanding at a CAGR of 12.6%. This growth is fueled by ongoing advancements in cancer treatment and increasing adoption of CAR-T therapies.

CAR-T Drugs Market Statical Scope

The rising prevalence of cancer and the urgent need to treat certain blood cancers are supporting the wide adoption of CAR-T drugs, which use the patient's own immune system to target and kill cancer cells.

Similarly, these are also renowned as living drugs used in CAR-T cell therapies, which include Tisagenlecleucel (Kymriah), Axicabtagene ciloleucel (Yescarta), Brexucabtagene autoleucel (Tecartus), Lisocabtagene maraleucel (Breyanzi), Idecabtagene vicleucel (Abecma), and Ciltacabtagene autoleucel (Carvykti). Furthermore, these FDA-approved drugs are specifically used in the treatment of certain types of blood cancers like acute lymphoblastic leukemia, large B-cell lymphomas, and multiple myeloma.

However, the CAR-T drugs market is driven by the leading market players like Gilead Sciences, Bristol Myers Squibb, Novartis AG, Johnson & Johnson, Autolus Therapeutics, Allogene Therapeutics, AstraZeneca, Carsgen Therapeutics, JW Therapeutics, and ImmunoACT. For instance, in December 2025, Bristol Myers Squibb revealed that the U.S. FDA approved its first and only CAR-T cell therapy, named Breyanzi, for the treatment of adults who are dealing with relapsed and refractory marginal zone lymphoma.

To begin with, in April 2024, Smt. Droupadi Murmu, the President of India, announced the launch of India's first homegrown CAR-T cell therapy named NexCAR19 for cancer, which is the World's most affordable and accessible CAR-T therapy, developed by Tata Memorial Centre, IIT Bombay, and ImmunoACT. Studies reveal that CAR-T researchers face barriers in advancing research and proposing collaborative strategies.

Moreover, the Ministry of Health and Family Welfare, the Government of India, has launched various government schemes such as the Biotechnology Industry Partnership Programme (BIPP), Promoting Academic Research Conversion to Enterprise (PACE), and the National Biopharma Mission (NBM). They are launched to promote the development, manufacturing, clinical workflow, and the evaluation of the safety and efficacy of living drugs.

Consequently, the North American government aims to expand patient access to specialized healthcare through reimbursement policies and a regulatory framework. Similarly, the government-led ‘Make in India' initiative, drug approvals in China, and a streamlined regulatory environment drive the CAR-T drugs market in the Asia Pacific.

CAR-T Drugs Market Share, By Region, 2025 (%)

• North America - North America leads with 40% of the market, driven by its advanced healthcare infrastructure, cutting-edge medical research, and significant investments in the development of innovative treatments, including those targeting hematoma and solid tumors.
• LAMEA - The LAMEA region (Latin America, the Middle East, and Africa) holds 10% of the market, a smaller share due to limited healthcare infrastructure, lower market adoption of advanced therapies, and fewer resources for large-scale research.
• Europe - Europe holds 30% of the market, with a strong healthcare system and investment in cancer research, although its share is smaller than North America due to slower regulatory processes and market dynamics.
• Asia-Pacific - Asia-Pacific accounts for 20% of the market, growing rapidly due to increasing healthcare investments, a large and aging population, and improving access to advanced cancer treatments, positioning the region for further market expansion.

CAR-T Drugs Market Share, By Type, 2025 (%)

• Single Target - Single target therapies focus on attacking one specific antigen or receptor on the surface of cancer cells. It holds 60% of the market, dominating due to its straightforward approach and proven efficacy in targeting specific cancer types with higher precision.
• Multiple Targets - Multiple target therapies aim to target various antigens or receptors on cancer cells simultaneously, offering a broader treatment approach. With 40% of the market, this segment is gaining momentum due to its potential to overcome resistance mechanisms by targeting different aspects of the tumor's biology.

CAR-T Drugs Market Share, By Application, 2025 (%)

• Hematoma - Hematoma refers to the localized collection of blood outside blood vessels, often treated with therapies that target bleeding or clotting factors. This segment holds 50% of the market, reflecting the significant need for therapies to treat blood-related issues such as hematomas, particularly in acute settings.
• Solid Tumors - Solid tumors, which include cancers like breast, lung, and prostate, are often treated with therapies targeting tumor-specific antigens. It holds 40% of the market, as it is a major application of cancer immunotherapies, although slightly less than hematoma due to the complexity and heterogeneity of solid tumors.
• Others - This category covers other applications of therapies targeting conditions not classified under hematoma or solid tumors, including rare cancers and less common diseases. It represents 10% of the market, a smaller share as it focuses on niche or less common medical conditions.